---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-107874"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:32:17.941135+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jasper Q3 net loss $18.7M; BEACON investigation finds no drug quality issues; cash $50.9M

## Summary
- Net loss of $18.7M ($1.13 per share); R&D expense $14.4M, G&A $4.8M.
- Cash $50.9M at Sep 30; completed $30M stock/warrant offering extending runway into H1 2026.
- BEACON investigation: no drug substance or product issues; focus now on clinical site processes.
- Final BEACON conclusions expected Q4 2025; additional data from BEACON and OLE in H1 Q1 2026 for Phase 2b dose selection.
- Initial data from ETESIAN asthma study planned for Q4 2025.

## SEC filing metadata
- accession: 0001213900-25-107874
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/0001213900-25-107874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea0264586-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-107874
- JSON: https://secwatch.observer/filing/0001213900-25-107874.json
- Plain text: https://secwatch.observer/filing/0001213900-25-107874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.